Mesoblast (MEOBF) Gains from Investment Securities (2014 - 2023)
Mesoblast's (MEOBF) quarterly Gains from Investment Securities came in at -$8.8 million in Q2 2023, down 2711.22% year-over-year from $335896.9 in Q2 2022, and down 765.48% quarter-over-quarter from $1.3 million in Q1 2023.
Powered by 
Analysis
Mesoblast (MEOBF) Gains from Investment Securities (2014 - 2023) Analysis & Trends
Mesoblast has disclosed Gains from Investment Securities across 10 years of filings, most recently posting -$8.8 million for Q2 2023.
- In Q2 2023, Gains from Investment Securities fell 2711.22% year-over-year to -$8.8 million; the TTM figure through Jun 2023 stood at -$10.4 million (down 3738.01% YoY), while the FY2026 annual figure was -$12.1 million, down 180.99% from the prior year.
- Gains from Investment Securities came in at -$8.8 million for Q2 2023 at Mesoblast, down from $1.3 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $15.1 million in Q3 2020 to a low of -$36.8 million in Q2 2021.
- Average Gains from Investment Securities over 5 years is -$2.0 million, with a median of -$288000.0 recorded in 2019.
- Year-over-year, Gains from Investment Securities sank 7918.18% in 2019 and jumped 5345.49% in 2020.
- Over 5 years, Gains from Investment Securities stood at -$882000.0 in 2019, then soared by 265.76% to $1.5 million in 2020, then sank by 124.01% to -$351000.0 in 2021, then soared by 533.05% to $1.5 million in 2022, then sank by 677.04% to -$8.8 million in 2023.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$8.8 million in Q2 2023, $1.3 million in Q1 2023, and $1.5 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -8.77 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Sep 30, 2022 | -4.47 Mn |
| Jun 30, 2022 | -312,000.00 |
| Mar 31, 2022 | 672,000.00 |
| Dec 31, 2021 | -351,000.00 |
| Sep 30, 2021 | -280,000.00 |
| Jun 30, 2021 | -36.79 Mn |
| Mar 31, 2021 | 1.53 Mn |
| Dec 31, 2020 | 1.46 Mn |
| Sep 30, 2020 | 15.11 Mn |
| Mar 31, 2020 | 2.16 Mn |
| Dec 31, 2019 | -882,000.00 |
| Sep 30, 2019 | -288,000.00 |
| Jun 30, 2019 | -2.91 Mn |
| Mar 31, 2019 | -2.72 Mn |
| Dec 31, 2018 | -11,000.00 |
| Sep 30, 2018 | 622,000.00 |
| Jun 30, 2018 | 2.66 Mn |